Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL691540 | 1.00 | KDM4E (0.35) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL232206 | 0.97 | KDM4E (0.36) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL515770 | 0.93 | SOAT1 (0.38) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL562372 | 0.93 | SOAT1 (0.38) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL316931 | 0.91 | SOAT1 (0.41) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL561964 | 0.91 | SOAT1 (0.41) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL154713 | 0.90 | SOAT1 (0.39) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL250912 | 0.88 | SOAT1 (0.42) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4151443 | 0.88 | SOAT1 (0.42) | KDM4ETP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL6214815 | 0.87 | LMNA (0.36) | KDM4ETP53CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583888-B2 | Bi-specific extracellular matrix binding peptides and methods of use thereof | UNIVERSITY OF TARTU (EE) | 2026-03-24 | — | — | US | disclosed |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250361270-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2025-11-27 | — | — | US | disclosed |
| US-12290569-B2 | Methods and compositions using peptides and proteins with c-terminal elements | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-05-06 | — | — | US | disclosed |
| US-12195558-B2 | Targeted delivery system and methods of use therefor | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-14 | — | — | US | disclosed |
| CN-114685661-B | Matrix metalloproteinase cleavable and serine proteinase cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114685611-B | Matrix metalloproteinase cleavable and serine proteinase cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119119209-A | Matrix metalloproteinase cleavable and serine proteinase cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240391953-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2024-11-28 | — | — | US | disclosed |
| CN-114907446-B | Matrix metalloproteinase cleavable and serine proteinase cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2024-08-02 | — | — | CN | disclosed |
| US-7332277-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080008650-A1 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2008-01-10 | — | — | US | disclosed |
| US-20070219134-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2007-09-20 | — | — | US | disclosed |
| WO-2007090194-A2 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070178478-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-08-02 | — | — | US | disclosed |
| WO-2007076501-A2 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070122835-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-05-31 | — | — | US | disclosed |
| EP-1484338-B1 | Methods and compositions for inhibiting neoplastic cell growth | GENENTECH INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060160105-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060121452-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008650-A1 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | ESR2, PROKR1, CXCL12 | GLA 3938/4885KDM4E 4076/4885TP53 2461/4885 |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CMKLR2, CRKL, CMKLR1 | GLA 4084/4885KDM4E 2252/4885TP53 666/4885 |
| US-20070219134-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | SLC39A3, SLC39A11, CCL2 | GLA 2288/4885KDM4E 4335/4885TP53 65/4885 |
| US-12583888-B2 | Bi-specific extracellular matrix binding peptides and methods of use thereof | FN1, EDNRB, TNFSF11 | GLA 4695/4885KDM4E 1503/4885TP53 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.